A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522398-12-00

Acronym

2215-CL-5201

Enrollment

Registered

2026-01-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced or metastatic NSCLC

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026